Figure 3.
Ligustrazine represses the expression of cytoskeleton proteins in hypoxia-induced PMCs. (a) Immunofluorescence analysis of cytoskeleton protein (vinculin) expression in hypoxia-induced PMCs treated with 20 μM ligustrazine for 24 h (200x). (b) Western blot analysis of cytoskeleton protein (vinculin) expression in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. (c) qRT-PCR analysis of mRNA levels of cytoskeleton molecules (vinculin) in hypoxia-induced PMCs treated with different concentrations of ligustrazine for 24 h. Compared with the control, ∗P < 0.05 and ∗∗P < 0.01.